|Bid||2.8600 x 3200|
|Ask||2.9300 x 1800|
|Day's Range||2.8750 - 3.0250|
|52 Week Range||2.5000 - 6.7900|
|Beta (5Y Monthly)||1.40|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 06, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
A mix of marketwide headwinds and company-specific events weighed on these three biotech stocks in November.
November has been brutal for biotech stocks. Agenus' shares have been on a downward spiral ever since the FDA requested the company withdraw its BLA for the checkpoint inhibitor balstilimab last month.
LEXINGTON, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Dr. Garo Armen, Chairman and Chief Executive Officer of Agenus and Dr. Steven O’Day, Chief Medical Officer, will participate in a fireside chat hosted by Evercore on Tuesday, November 30th, 2021 at 1:50 PM EST. Registration can be